Stereotaxis (STXS) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Speaker0 Good afternoon. Thank you for joining us for Stereotaxis First Quarter twenty twenty five Earnings Conference Call. Certain statements during the conference call and question and answer period to follow may relate to future events, expectations and as such constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and ...

2025 年海外收入有望维持高速增长，27 省联盟集采续约有望于2H25启动。海外1Q25 手术量1,000+台 （同比双位数增长），其中约一半手术使用压力导管。海外业务中拉美市场增速最高。从收入角度，公 司预计全年海外增速仍将维持较高增速，但增速相较2024 年将有所放缓（2024 年海外收入同比 +52%）。国内1Q25 手术量5,000+台（同比个位数增长），其中约30%使用压力导管，目前公司进入了 约50 家在国内手术量排名前200 的手术中心，入院数量仍有进一步提升空间。 福建牵头的27 省联盟电生理集采续约有望于2H25 启动，预计中标价仍将有温和的下降压力。 关税战背景下，公司加快原材料国产化比例。公司2024 年原材料中进口比例约40%（vs 2022 年：约 60%），由美国进口原材料比例约10%（vs 2022 年：约30%），美国进口原材料比例并不高。公司目前 正在加快对美国进口原材料的替代，该部分原材料此前多有美国、中国两个供方，目前正逐步加大中国 供方比例。 研发管线顺利推进：1）PFA：参股的商阳医疗PFA 产品已于今年4 月获批，目前在挂网过程中；此 外，公司自研导管预计也将于2 ...

Investment Rating - The report maintains a "Recommended" rating for the company, with a current stock price of 21.77 yuan [1]. Core Insights - The company achieved a revenue of 104 million yuan in Q1 2025, representing a year-on-year increase of 16.77%. The net profit attributable to the parent company was 17.87 million yuan, a significant increase of 328.63% year-on-year, and the net profit after deducting non-recurring items was 12.56 million yuan, turning around from a loss of 1.35 million yuan in the same period last year [5]. - The company is positioned as a leading domestic player in the electrophysiology field, benefiting from rapid expansion in this sector. The report forecasts continued strong growth, with projected revenues of 522 million yuan, 687 million yuan, and 934 million yuan for 2025, 2026, and 2027 respectively, and net profits of 76 million yuan, 134 million yuan, and 215 million yuan for the same years [11]. Financial Summary - Revenue growth is expected to be robust, with year-on-year growth rates of 26.5%, 25.5%, 26.4%, 31.5%, and 36.0% from 2023 to 2027 [7]. - The net profit is projected to grow significantly, with year-on-year increases of 91.4%, 815.4%, 46.8%, 75.7%, and 60.0% over the same period [7]. - The gross margin is expected to stabilize around 61.8% to 62.8%, while the net margin is projected to improve from 12.6% in 2024 to 23.0% in 2027 [7][13]. - The company maintains a low debt level, with a debt-to-asset ratio of only 8.1% [8]. Operational Efficiency - The company has effectively controlled its operating expenses, with a sales expense ratio of 26.29% in Q1, down by 1.20 percentage points year-on-year, and a management expense ratio of 10.87%, down by 0.63 percentage points [8]. - Research and development expenses accounted for 19.88% of revenue, reflecting a focus on core projects [8]. Product Development - The company has introduced new products, including a PFA product approved in April 2025, which is expected to enhance its market position [8]. - The company is also working on a self-developed pressure pulse ablation catheter, with a registration application planned for 2025, further expanding its product portfolio [11].

Stereotaxis, Inc. (NYSE:STXS) Q4 2024 - Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants David Fischel - Chairman and CEO Kimberly Peery - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Adam Maeder - Piper Sandler Jason Wittes - ROTH Capital Partners Operator Good morning. Thank you for joining us for Stereotaxis Fourth Quarter and Full Year 2024 Earnings Conference Call. Certain statements during the conference call and question and answer period to foll ...